# Metabolic reprogramming orchestrates an immunosuppressive microenvironment in anaplastic thyroid cancer: mechanisms and clinical perspectives

## TL;DR

This paper explores how metabolic changes in anaplastic thyroid cancer create an environment that suppresses the immune system, offering new therapeutic strategies.

## Contribution

The paper provides a systematic review of how metabolic reprogramming in ATC shapes an immunosuppressive tumor microenvironment and identifies potential therapeutic targets.

## Key findings

- Metabolic alterations in ATC promote immunosuppressive tumor microenvironments through mechanisms like nutrient competition and metabolite accumulation.
- Metabolic crosstalk fosters pro-tumorigenic immune cell populations such as M2 macrophages and regulatory T cells.
- Combining metabolic inhibitors with immune checkpoint blockade shows promise in overcoming resistance in ATC.

## Abstract

Anaplastic Thyroid Carcinoma (ATC) represents one of the most aggressive and lethal human malignancies, characterized by rapid progression, profound therapy resistance, and a dismal prognosis. Recent advances have underscored metabolic reprogramming as a cornerstone of ATC pathogenesis, enabling tumor cells to adapt to a hostile microenvironment, sustain proliferation, and evade immune destruction. This review systematically delineates how metabolic alterations in ATC—spanning enhanced glycolysis, deregulated lipid metabolism, and aberrant amino acid utilization—orchestrate a profoundly immunosuppressive tumor immune microenvironment (TIME). We explore the mechanistic links between tumor metabolism and immune dysfunction, including nutrient competition-induced energy deficits in effector immune cells, accumulation of immunosuppressive metabolites, and metabolic regulation of immune checkpoint expression. Furthermore, we discuss the impact of metabolic crosstalk on immune cell phenotypes, fostering the recruitment and polarization of pro-tumorigenic immune populations such as M2 macrophages, regulatory T cells, and myeloid-derived suppressor cells. Clinically, we highlight the therapeutic promise of targeting key metabolic nodes and review emerging combination strategies that integrate metabolic inhibitors with immune checkpoint blockade to overcome resistance and enhance antitumor immunity. By synthesizing foundational insights with cutting-edge preclinical and clinical evidence, this review aims to provide a cohesive mechanistic framework and identify novel, metabolism-based therapeutic vulnerabilities for precision immunotherapy in ATC.